APA (7th ed.) Citation

Simonelli, M., Lorusso, D., Homicsko, K., Seguy, F., Kinder, M., Liu, Q., . . . Kitano, S. (2024). 617MO Safety and tolerability of INCB123667, a selective CDK2 inhibitor, in patients (pts) with advanced solid tumors: A phase I study. Annals of Oncology, 35, S495. https://doi.org/10.1016/j.annonc.2024.08.684

Chicago Style (17th ed.) Citation

Simonelli, M., D. Lorusso, K. Homicsko, F. Seguy, M. Kinder, Q. Liu, E. Croft, and S. Kitano. "617MO Safety and Tolerability of INCB123667, a Selective CDK2 Inhibitor, in Patients (pts) with Advanced Solid Tumors: A phase I Study." Annals of Oncology 35 (2024): S495. https://doi.org/10.1016/j.annonc.2024.08.684.

MLA (9th ed.) Citation

Simonelli, M., et al. "617MO Safety and Tolerability of INCB123667, a Selective CDK2 Inhibitor, in Patients (pts) with Advanced Solid Tumors: A phase I Study." Annals of Oncology, vol. 35, 2024, p. S495, https://doi.org/10.1016/j.annonc.2024.08.684.